Adalimumab (TNFSF2/TNF-alpha/TNFA) Antibody, Monoclonal
| Code | Size | Price |
|---|
| PSI-10-186-0.1mg | 0.1mg | £657.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: IgG1-kappa
Antibody Clonality: Recombinant Antibody
Regulatory Status: RUO
Shipping:
blue ice
Storage:
Store at -80˚C
Documents
Further Information
Additional Names:
D2E7
Background:
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor?2,?3. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA?1. This drug is frequently known as?Humira. It is produced by recombinant DNA technology using a mammalian cell expression system. This drug is available in a prefilled syringe form and convenient pen form for subcutaneous self-administered doses?1. A new biosimilar to adalimumab, named?adalimumab-adaz, was approved by the FDA on October 31, 2018. This biosimilar is known as?Hyrimoz, and is a trademark of Novartis AG?9.
Buffer:
PBS buffer pH7.5
Concentration:
batch dependent
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Homo sapiens / TNFSF2/TNF-alpha/TNFA [Homo sapiens]
NCBI Organism:
homo sapiens
Purification:
>95%
Research Area:
Drug Analogues
Source:
CHO cells
User NOte:
Optimal dilutions for each application to be determined by the researcher.